PT010
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
PT010 is a fixed triple-combination product consisting of a long-acting muscarinic antagonist (LAMA [glycopyrrolate]), a long-acting beta 2 agonist (LABA [formoterol]), and an inhaled corticosteroid (ICS [budesonide]). PT010 is in Phase III development for the treatment of moderate to very severe COPD, and in Phase II development for the treatment of moderate to severe persistent asthma.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 PT010 : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
13 Figure 1: PT010 for COPD – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of PT010 for COPD
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of PT010 for COPD
17 Figure 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: PT010 drug profile
7 Table 2: PT010 Phase III data in COPD
9 Table 3: PT010 Phase III trials in COPD
18 Table 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Incruse 
Sign up to the